Literature DB >> 16328893

Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety.

E Ciesielska1, K Studzian, M Wasowska, I Oszczapowicz, L Szmigiero.   

Abstract

Daunorubicin (DRB) and its two analogues containing a trisubstituted amidino group at the C-3' position of the daunosamine moiety have been compared regarding their cytotoxic activity, cellular uptake, subcellular localization and DNA damaging properties. An analogue containing in the amidino group a morpholine moiety (DRBM) as well as an analogue with a hexamethyleneimine moiety (DRBH), tested against cultured L1210 cells, exhibited lower cytotoxicity then DRB. The decrease of cytotoxic activity was not related to cellular uptake and subcellular localization of drugs. Although all tested drugs were active in the induction of DNA breaks and DNA-protein crosslinks, they differed in the mechanism of induction of DNA lesions. DRB produced DNA breaks mediated solely by topoisomerase II, whereas DRBM and DRBH induced two types of DNA breaks by two separate processes. The first is related to the inhibition of topoisomerase II and the second presumably reflects a covalent binding of drug metabolites to DNA. It is hypothesized that the replacement of the primary amino group (-NH(2)) at the C-3' position of the daunosamine moiety by a trisubstituted amidino group (-N=CH-NRR) may be a route to the synthesis of anthracycline derivatives with enhanced ability to form covalent adducts to DNA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16328893     DOI: 10.1007/s10565-005-0142-1

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  6 in total

1.  Synthesis and biological properties of oxazolinodaunorubicin--a new derivative of daunorubicin with a modified daunosamine moiety.

Authors:  Malgorzata Lukawska; Joanna Wietrzyk; Adam Opolski; Janusz Oszczapowicz; Irena Oszczapowicz
Journal:  Invest New Drugs       Date:  2009-08-28       Impact factor: 3.850

2.  Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin.

Authors:  Ewa Gajewski; Shikha Gaur; Steven A Akman; Linda Matsumoto; Josephus N A van Balgooy; James H Doroshow
Journal:  Biochem Pharmacol       Date:  2007-03-24       Impact factor: 5.858

3.  The influence of pH and temperature on the stability of N-[(piperidine)methylene]daunorubicin Hydrochloride and a comparison of the stability of daunorubicin and its four new amidine derivatives in aqueous solutions.

Authors:  Mikołaj Piekarski; Agnieszka Dołhań; Judyta Cielecka-Piontek; Przemysław Zalewski; Witold Kycler; Aleksandra Kaczmarek; Artur Firlej; Irena Oszczapowicz; Anna Jelińska
Journal:  ScientificWorldJournal       Date:  2014-02-06

4.  Topoisomerases inhibition and DNA binding mode of daunomycin-oligoarginine conjugate.

Authors:  Valeria Visone; Ildikó Szabó; Giuseppe Perugino; Ferenc Hudecz; Zoltán Bánóczi; Anna Valenti
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

5.  Subcellular localization of anthracyclines in cultured rat cardiomyoblasts as possible predictors of cardiotoxicity.

Authors:  Kazimierz Studzian; Krzysztof Kik; Malgorzata Lukawska; Irena Oszczapowicz; Malgorzata Strek; Leszek Szmigiero
Journal:  Invest New Drugs       Date:  2015-08-14       Impact factor: 3.850

Review 6.  Emerging Therapeutic Targets Against Toxoplasma gondii: Update on DNA Repair Response Inhibitors and Genotoxic Drugs.

Authors:  Sergio O Angel; Laura Vanagas; Diego M Ruiz; Constanza Cristaldi; Ana M Saldarriaga Cartagena; William J Sullivan
Journal:  Front Cell Infect Microbiol       Date:  2020-06-12       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.